Skip to main content
Top

07-07-2021 | ADA 2021 | Conference coverage | News

News in brief

​​​​​​​Better 5-year outcomes for RYGB with silastic ring vs sleeve gastrectomy in type 2 diabetes

Author: Eleanor McDermid

print
PRINT
insite
SEARCH

medwireNews: People with obesity are more likely to achieve sustained remission of type 2 diabetes if they undergo Roux-en-Y gastric bypass (RYGB) with a silastic band rather than sleeve gastrectomy, show the 5-year findings of a randomized trial.

Five years after surgery, 47% of the 53 people randomly assigned to undergo RYGB with a silastic band had remission of diabetes, defined as glycated hemoglobin levels below 42 mmol/mol (6%) without use of diabetes medications.

The corresponding rate for the 55 people assigned to undergo sleeve gastrectomy was 33%, giving a significant adjusted odds ratio of 6.78 favoring the RYGB group, Rinki Murphy (University of Auckland, New Zealand) reported at the virtual ADA 81st Scientific Sessions.

Bodyweight decreased by an average of 21.1% and 10.9% between surgery and 5 years in the RYGB and sleeve gastrectomy groups, respectively, with the difference between the two groups being statistically significant.

BMI reached its lowest point around 12 months after surgery, after which it increased gradually in both groups. “However, the gap between the bypass and the sleeve widened over time, with less weight regain after the bypass,” said Murphy.

Complication rates were similar in both groups across the 5 years, but the reduction in bone mineral density was significantly greater in the RYGB than sleeve gastrectomy group.

Murphy cautioned that use of a 6.5 cm silastic ring in this study, to prevent gastric pouch dilation, means the results may not apply to unbanded RYGB.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

ADA Scientific Sessions; 25–29 June 2021

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »